Article Details
Retrieved on: 2025-02-22 08:52:05
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Its third gene therapy, Lyfgenia (lovotibeglogene autotemcel), is approved for the treatment of sickle cell disease. In a closely competitive race, ...
Article found on: www.pharmaceutical-technology.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here